Humacyte is a pre-revenue biotech company that has delivered outsized gains to shareholders in 2024. But is the small-cap stock a good buy right now?
On April 16th, we reported on a stock trade by Senator Tommy Tuberville that looked suspicious to us. The stock has now risen 220% in the month since then. The stock in question was Humacyte, $HUMA. It's...
$HUMA earnings were just released. Here is a look at recent trades of $HUMA by people who might have an edge.CongressMembers of Congress have disclosed trades of $HUMA stock 5 times in the last quarter....
In a new disclosure filed today, U.S. Senator Tommy Tuberville reported the purchase of $1,001 - $15,000 of Humacyte Inc, in a trade that took place on March 21. Since that trade was made, the stock has...
Monday U.S. Economic Lookahead Home builder confidence index (Feb.) Featured Earnings ...
Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement...
DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally...
-- Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease-- -- Small-diameter HAV...
Thursday, July 14, 2022 @ 11:30 a.m. ET...
Industry leader brings deep expertise in international drug development, strategic leadership, and corporate partnering for biopharmaceutical companies...